SEC ownership of FILANA THERAPEUTICS, INC.

Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001069530.

Comparable stake leader

Nachtrab Matthew

Disclosed value leader

VANGUARD GROUP INC

Comparable rows

50/50

Latest evidence

31 Mar 2026

Top shareholders Insider holders Latest transactions

Public ticker: FLNA on Nasdaq
Parsed ownership sources: 13D/G and 13F
Largest SEC-reported holder: Nachtrab Matthew
Latest 13D/G holder: Nachtrab Matthew
Latest parsed ownership date: 31 Mar 2026
Issuer CIK: 0001069530
Issuer location: Austin, TX

Ownership snapshot

Top shareholders of FILANA THERAPEUTICS, INC. (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader

Nachtrab Matthew

Disclosed value leader

VANGUARD GROUP INC

Comparable rows

50/50

Latest evidence

31 Mar 2026

13D/G 13F Lead comparable stake: 4.7% 13D/G row: Nachtrab Matthew Showing 1-8 of 50 holder rows.

Quick read

Nachtrab Matthew leads the comparable SEC ownership view at 4.7%.

50 of 50 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens Nachtrab Matthew's linked filing trail.

Comparable ownership Top 5

Nachtrab Matthew 4.7%

VANGUARD GROUP INC 4.5%

BlackRock, Inc. 3.2%

MARSHALL WACE, LLP 4.2%

TWO SIGMA INVESTMENTS, LP 4.1%

Ownership % is shown only when SEC disclosures are safely comparable across share classes.

Detailed SEC evidence table Showing 1-8 of 50 holder rows

Holder	Evidence	Ownership %	Position	12M Net Δ	As of
Nachtrab Matthew	13D/G 13D/G	4.7%	$3,560,189 2,267,636 shares	$0	16 Aug 2024
VANGUARD GROUP INC	13D/G The Vanguard Group 13D/G	4.5%	$3,927,830 2,170,072 shares	$0	30 Jun 2025
BlackRock, Inc.	13D/G 13F Company 13D/G 13F	3.2%	$2,797,129 1,545,375 shares	$0	30 Jun 2025
MARSHALL WACE, LLP	13F Company 13F	4.2%	$3,401,201 2,012,543 shares	—	31 Mar 2026
TWO SIGMA INVESTMENTS, LP	13F Company 13F	4.1%	$3,361,096 1,988,814 shares	—	31 Mar 2026
VANGUARD CAPITAL MANAGEMENT LLC	13F Company 13F	4%	$3,263,294 1,930,943 shares	—	31 Mar 2026
GEODE CAPITAL MANAGEMENT, LLC	13F Company 13F	1.2%	$1,008,020 596,242 shares	—	31 Mar 2026
D. E. Shaw & Co., Inc.	13F Company 13F	1.2%	$945,056 559,205 shares	—	31 Mar 2026

How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Forms 3/4/5 flow

Insider trading overview

Net insider flow leans to buying over the last 12 months. Net value: +$1,231,784.

Buys

$1,231,784

Insiders: 3

Sells

Insiders: 0

Net

+$1,231,784

Shares: +490,823

Window

Last 12 months

4 rolling buckets

Buy value Sell value

Shares: 490,823 Shares: 0

Window (months)	Buy shares	Buy value	Sell value	Net value
0-3	0	$0	$0	$0
3-6	0	$0	$0	$0
6-9	490,823	$1,231,784	$0	+$1,231,784
9-12	0	$0	$0	$0

Reporting owners

Insider holders from Forms 3/4/5

Showing 1-16 of 16 reporting-owner rows connected to FILANA THERAPEUTICS, INC.. Open a relationship link for the CIK-to-CIK filing trail.

Rows

Largest Forms 3/4/5 holder

Sanford Robertson

Net 12M change

+$1,231,784

Latest report

24 Nov 2025

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Valuation	Report Date
Sanford Robertson	Director	$25,241,772			Mixed	16 May 2024
Richard Barry	President & CEO, Director	$12,711,045	+$1,166,904	+10%	Mixed	20 Nov 2025
Robert Christopher Cook	Chief Operating & Legal Office	$1,726,939	+$39,940	+2.4%	Mixed	30 Sep 2025
Freda Nassif	Chief Business Officer	$1,687,000			Mixed	17 Apr 2025
James William Kupiec	Chief Medical Officer	$1,687,000			Mixed	29 Nov 2024
Jaren Landen	Chief Clinical Dev. Officer	$1,433,950			Mixed	18 Nov 2024
Remi Barbier	President & CEO, Director	$843,500			Mixed	20 May 2024
Robert Z. Gussin	Director	$253,050			Mixed	23 May 2025
Robert Eugene Anderson Jr.	Director	$193,640	+$24,940	+15%	Mixed	24 Nov 2025
Michael J. O Donnell	Director	$168,700			Mixed	23 May 2025
Pierre Gravier	Director	$168,700			Mixed	23 May 2025
Claude Nicaise	Director	$168,700			Mixed	23 May 2025
Patrick J. MD Scannon PhD	Director	$168,700			Mixed	23 May 2025
Eric J. Schoen	Chief Financial Officer	$44,390			Filing P/S	17 Apr 2025
Nadav Friedmann	Chief Medical Officer, Director	$2,495			Mixed	31 Dec 2022
Dawn Carter Bir	Director				Mixed	21 Oct 2025

Recent insider transactions for FILANA THERAPEUTICS, INC.

Showing up to 300 recent insider transactions from the last 12 months.

Insider	Symbol	Class	Transaction	%	SEC-reported value	SEC-reported price	Shares	Shares owned	Date	Ownership
Robert Eugene Anderson Jr.	SAVA	Common Stock	Purchase		$24,940	$2.90	8,600	8,600	24 Nov 2025	Direct
Richard Barry	SAVA	Common Stock	Purchase	19%	$414,000	$2.76	150,000	938,060	20 Nov 2025	By Trust
Richard Barry	SAVA	Common Stock	Purchase	10.3%	$201,809	$2.75	73,385	788,060	19 Nov 2025	By Trust
Dawn Carter Bir	SAVA	Stock Option (Right to Buy)	Award				53,000	53,000	21 Oct 2025	Direct
Robert Christopher Cook	SAVA	Common Stock	Purchase		$39,940	$2.91	13,725	13,725	30 Sep 2025	Direct
Richard Barry	SAVA	Common Stock	Purchase	1.01%	$16,352	$2.28	7,172	714,675	22 Sep 2025	By Trust
Richard Barry	SAVA	Common Stock	Purchase	7.17%	$108,319	$2.29	47,308	707,503	19 Sep 2025	By Trust
Richard Barry	SAVA	Common Stock	Purchase	40.6%	$426,424	$2.24	190,633	660,195	18 Sep 2025	By Trust

^* marks a reported price that did not pass the local price check.